Trial · NCT07588984
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 29
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Body Weight | Monthly, Baseline through Month 12 (and Months 18 & 24 for FLOURISH GLP-1 arms) | Change from baseline in body weight (kg/lbs) measured via connected scale. |
| Primary | Change in fasting glucose | Baseline, Month 2, Month 4, Month 8, Month 12 | Change from baseline in fasting glucose (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device. |
| Primary | Change in HbA1c | Baseline, Month 2, Month 4, Month 8, Month 12 | Change from baseline in HbA1c (mmol/mol and percentage) measured via Tasso+ capillary blood collection device. |
| Primary | Change in LDL cholesterol | Baseline, Month 2, Month 4, Month 8, Month 12 | Change from baseline in LDL cholesterol (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device. |
| Primary | Change in HDL cholesterol | Baseline, Month 2, Month 4, Month 8, Month 12 | Change from baseline in HDL cholesterol (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device. |
| Primary | Change in total cholesterol | Baseline, Month 2, Month 4, Month 8, Month 12 | Change from baseline in total cholesterol (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device. |
| Primary | Change in triglycerides | Baseline, Month 2, Month 4, Month 8, Month 12 | Change from baseline in triglycerides (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device. |
| Primary | Change in Body Composition | Monthly, Baseline through Month 12 ((and Months 18 & 24 for FLOURISH GLP-1 arms) | Change from baseline in estimated body composition metrics (lean mass, fat mass percentage) as measured via in-app BodyScan feature. |
| Primary | GLP-1 Side Effect Profile | Baseline (pre-treatment), Monthly through Month 12 | Number, severity, and tolerance of GLP-1 medication-related side effects (nausea, vomiting, diarrhea, constipation, headache, fatigue, injection site reactions) assessed via monthly self-report. Applicable to GLP-1 arms only. |
| Secondary | Change in heart rate variability (HRV) | Collected monthly from baseline through month 12 and at months 18 and 24 for the FLOURISH GLP-1 program. | Change in heart rate variability (HRV) from baseline measured via in-app FaceScan feature (all arms) and wearables (select arms). |
| Secondary | Change in resting heart rate (RHR) | Collected monthly from baseline through month 12 and at months 18 and 24 for the FLOURISH GLP-1 program. | Change in resting heart rate (RHR) from baseline measured via wearables (select arms). |
| Secondary | Change in Peripheral Capillary Oxygen Saturation (SpO2) | Collected monthly from baseline through month 12 and at months 18 and 24 for the FLOURISH GLP-1 program. | Change in Peripheral Capillary Oxygen Saturation (SpO2) from baseline measured via wearables (select arms). |
| Secondary | Change in sleep duration | Collected monthly from baseline through month 12 and at months 18 and 24 for the FLOURISH GLP-1 program. | Change in sleep duration (hours and minutes) from baseline measured via wearables (select arms). |
| Secondary | Change in time spent in sleep stages | Collected monthly from baseline through month 12 and at months 18 and 24 for the FLOURISH GLP-1 program. | Change in time spent in sleep stages (hours and minutes spent in each sleep stage) from baseline measured via wearables (select arms). |
| Secondary | Change in sleep continuity | Collected monthly from baseline through month 12 and at months 18 and 24 for the FLOURISH GLP-1 program. | Change from baseline in wearable-derived sleep continuity, assessed as sleep onset latency (SOL) and wake after sleep onset (WASO), measured in minutes. |
| Other | Depression symptoms | Baseline, Months 4, 8, 12 (and 18, 24 for FLOURISH GLP-1 arms) | Change from baseline in Patient Health Questionnaire-8 (PHQ-8) score. Minimum score = 0; maximum score = 24. Lower score indicate none/mild depression; higher scores indicate severe depression. |
| Other | Anxiety symptoms | Baseline, Months 4, 8, 12 (and 18, 24 for FLOURISH GLP-1 arms) | Change from baseline in Generalized Anxiety Disorder-7 (GAD-7) score. Minimum score = 0; maximum score = 21. Lower scores = minimal or no anxiety; higher scores = severe anxiety. |
| Other | Sleep disturbance | Baseline, Months 4, 8, 12 (and 18, 24 for FLOURISH GLP-1 arms) | Change from baseline on Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance 8-item scale. Minimum score = 8; maximum score = 40. Lower scores = minimal or no sleep disturbance; higher scores = severe sleep disturbance. |
| Other | Energy and Vitality | Baseline, Months 4, 8, 12 (and 18, 24 for FLOURISH GLP-1 arms) | Change from baseline on Subjective Vitality Scale. Minimum score = 6; maximum score = 42. Lower scores = worse outcome (lower energy and vitality); higher scores = better outcome (more energy and vitality) |
| Other | Health-related quality of life (HRQoL) | Baseline, Months 4, 8, 12 (and 18, 24 for FLOURISH GLP-1 arms) | Change from baseline on PROMIS PROPr composite score. Minimum score = -.022; maximum score = 1. Lower scores = worse outcome/health status ; higher scores = optimal health-related quality of life. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07588984/registered